Fidaxomicin warnings and precautions: Difference between revisions
(Created page with "==Warnings And Precautions== ===Not for Systemic Infections=== Since there is minimal systemic absorption of fidaxomicin, DIFICID is not effective for treatment of systemic ...") |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Fidaxomicin}} | |||
{{CMG}}; {{AE}} {{chetan}} | |||
==Warnings And Precautions== | ==Warnings And Precautions== | ||
| Line 13: | Line 17: | ||
===Development of Drug-Resistant Bacteria=== | ===Development of Drug-Resistant Bacteria=== | ||
Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. | Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DIFICID (FIDAXOMICIN) TABLET, FILM COATED [OPTIMER PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb | publisher = | date = | accessdate = }}</ref> | ||
==References== | |||
{{Reflist}} | |||
{{FDA}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Latest revision as of 04:14, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Warnings And Precautions
Not for Systemic Infections
Since there is minimal systemic absorption of fidaxomicin, DIFICID is not effective for treatment of systemic infections.
Hypersensitivity Reactions
Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with Fidaxomicin. If a severe hypersensitivity reaction occurs, DIFICID should be discontinued and appropriate therapy should be instituted.
Some patients with hypersensitivity reactions also reported a history of allergy to other macrolides. Physicians prescribing DIFICID to patients with a known macrolide allergy should be aware of the possibility of hypersensitivity reactions.
Development of Drug-Resistant Bacteria
Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.[1]
References
Adapted from the FDA Package Insert.